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Infections due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (ESBLEC) in non-
hospitalized patients seem to be emerging in different countries. Their incidence, epidemiology, and clinical
impact in the community have not been studied. We describe the epidemiology and clinical features of
infections caused by ESBLEC in nonhospitalized patients in Spain and the results of a case-control study
performed to investigate the risk factors associated with the acquisition of these organisms. The clonal
relatedness of the organisms was assessed by repetitive extragenic palindromic sequence PCR. The ESBLs and
the genes encoding the ESBLs were initially characterized by isoelectric focusing and PCR, respectively.
Forty-nine patients (76% with urinary tract infections, 22% with asymptomatic bacteriuria, and 2% with acute
cholangitis) were included. Six patients were bacteremic. Diabetes mellitus (odds ratio, 5.5; 95% confidence
interval, 1.6 to 18.7), previous fluoroquinolone use (odds ratio, 7.6; 95% confidence interval, 1.9 to 30.1),
recurrent urinary tract infections (odds ratio, 4.5; 95% confidence interval, 1.3 to 15.1), a previous hospital
admission (odds ratio, 18.2; 95% confidence interval, 5.3 to 61.1), and older age in male patients (odds ratio
per year, 1.03; 95% confidence interval, 1.03 to 1.05) were identified as risk factors by multivariate analysis. The
ESBLEC isolates were not clonally related. The ESBLs were characterized as members of the CTX-M-9 group,
the SHV group, and the TEM group in 64, 18, and 18% of the isolates, respectively. ESBLEC is an emergent
cause of urinary tract infections in nonhospitalized patients. There was no evidence of horizontal transmission
of ESBLEC strains. Avoidance of fluoroquinolone use in high-risk patients should be considered whenever
possible in order to avoid the selection of these organisms.
Extended-spectrum beta-lactamase (ESBL)-producing
members of the family Enterobacteriaceae are resistant to pen-
icillins, narrow- and extended-spectrum cephalosporins, and
aztreonam (4). ESBL-producing organisms are also frequently
resistant to aminoglycosides, trimethoprim-sulfamethoxazole,
and quinolones.
Until recently, most infections caused by ESBL-producing
Escherichia coli (ESBLEC) or Klebsiella pneumoniae had most-
ly been described as nosocomially acquired (4) or nursing home
related (32). However, some recent data suggest that infections
due to ESBL-producing organisms might be an emergent prob-
lem in outpatients in different countries (1, 8, 9, 11, 14, 15), but
detailed epidemiological data were not collected in most of
those studies. Moreover, the clinical relevance and the epide-
miology of these infections outside nursing homes have not
been studied.
In a recent nationwide study of ESBL-producing organisms
in Spain, 93% of ESBL-producing K. pneumoniae strains were
isolated from inpatients, while 51% of ESBL-producing E. coli
(ESBLEC) strains were isolated from outpatients (13) Conse-
quently, we conducted the study described in this report, in
which we describe and analyze the clinical features and the
epidemiology of infections due to ESBLEC in nonhospitalized
patients.
MATERIALS AND METHODS
Study population and design. The Microbiology Laboratory of the Hospital
Universitario Virgen Macarena in Seville, Spain, receives samples from the
hospital, the outpatient clinic, a nearby chronic-care hospital, and the primary
care services of an area with 450,000 inhabitants in the south of Spain.
The base population of the case-control study consisted of outpatients from
our area from whom a clinical sample had been sent to our laboratory for culture
and in whom a community-acquired infection was suspected. The sample could
have been obtained in a primary care office, the outpatient clinic, or the emer-
gency department. A case patient was defined as a person who had not been
admitted to a hospital during the previous month and from whom an ESBLEC
strain had been isolated from a clinical sample. For patients with recurrent
infections, only isolates from the first episodes were included. The case patients
were enrolled by collecting epidemiological data for all patients infected with
ESBLEC detected during the study period (January 2001 to May 2002). During
the study period, all patients in whom ESBLEC was detected were included
except those who had been admitted to a hospital for 48 h or more when the
sample was collected (10) and those who had been admitted to a hospital during
the previous month. For each case patient, two controls were randomly chosen
(by a computerized method) from among the patients from whom a sample had
been processed for culture during the same week. The same exclusion criteria
used for the case patients applied to the controls.
The following data were collected: demographic data, underlying diseases, the
severity of the underlying diseases according to the McCabe classification (19)
and the Charlson index (6), whether the patient had a history of recurrent urinary
tract infections (UTIs), whether the patient had used antibiotics in the previous
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2 months, whether the patient had received more than two cycles of antimicrobial
therapy in the previous year, whether the patient had been admitted to a hospital
or had had surgery in the last 12 months, whether the patient was a resident in
a nursing home, whether the patient had urinary catheters, and the empirical
treatment received. A structured questionnaire was used to collect the data. One
of the investigators (M. D. Navarro) filled out the questionnaires by using data
from the medical charts and interviewing the primary care doctors and the
patients or their closest relatives. Case patients and controls were excluded if
data were unavailable. The use of antimicrobial agents was determined in several
ways: in short, the patient was asked whether he or she remembered having used
antimicrobial agents or receiving therapy for any specific infection and whether
he or she remembered having received specific antimicrobials. Patients (case
patients and controls) and doctors were not informed about the purpose of the
study until the end of the interview. The infections were classified according to
the clinical and laboratory data. Patients with positive urine cultures (pure
culture of a single microorganism with a colony count105 CFU/ml) and clinical
signs related to the urinary tract were considered to have UTIs unless proven
otherwise. Asymptomatic patients with positive urine cultures were considered to
have asymptomatic bacteriuria. Patients with more than two episodes of UTIs
over a period of 6 months were considered to have recurrent UTIs. Antimicro-
bial treatment was considered appropriate when at least one antibiotic to which
the organism was susceptible or intermediately susceptible in vitro was admin-
istered.
The study protocol was approved by the local ethics committee. Due to the
observational character of the study, written informed consent was not required.
Microbiological methods. (i) Bacterial strains. Preliminary identification of
the isolates and determination of their susceptibilities to antimicrobial agents
were determined with the VITEK 2 system (bioMe´rieux, Hazelwood, Mo.). The
final identity was determined with API 20E strips (bioMe´rieux). The isolates
were screened for ESBL production by the disk diffusion method with Mueller-
Hinton agar plates (Oxoid) with disks containing 30 g of cefotaxime and
ceftazidime with or without 10 g of clavulanic acid (Oxoid, Basingstoke, United
Kingdom), as recommended by the NCCLS (21). ESBL production was con-
firmed by the microdilution method, as described by the NCCLS. A 3 twofold
dilution decrease in the MIC of either ceftazidime (GlaxoSmithKline, Green-
ford, Middlesex, United Kingdom) or cefotaxime (Sigma Laboratories, Madrid,
Spain) tested in combination with clavulanic acid (GlaxoSmithKline) versus the
MIC of each agent when it was tested alone was considered indicative of ESBL
production, according to the NCCLS guidelines (21).
(ii) Antimicrobial agent susceptibility assays. The in vitro activities of cefta-
zidime, cefotaxime, cefoxitin (Sigma), amoxicillin (Sigma) plus clavulanate,
imipenem (Merck Sharpe & Dohme, West Point, Pa.), ciprofloxacin (Sigma),
gentamicin (Sigma), amikacin (Sigma), and trimethoprim-sulfamethoxazole
(Galloso Laboratories, Madrid, Spain) were determined by a microdilution assay
according to the NCCLS guidelines (20). E. coli ATCC 25922, E. coli ATCC
35218, Pseudomonas aeruginosa ATCC 27853, and K. pneumoniae ATCC 700603
were used as control strains.
(iii) Molecular typing. The clonal relationships among the strains were deter-
mined by repetitive extragenic palindromic sequence PCR (REP-PCR) with
primers REP-1 (5-IIIGCGCCGICATCAGGC-3) and REP-2 (5-ACGTCTT
ATCAGGCCTAC-3) (31). DNA extraction was performed by boiling a colony
suspension at 100°C for 10 min. The supernatant from this suspension (24.5 l)
was used as the template for the PCR. All reactions were performed in a 50-l
volume with 2.0 U of Taq DNA polymerase (Invitrogen, Barcelona, Spain). The
cycling conditions were as follows: denaturation at 94°C for 3 min, followed by 30
amplification cycles (94°C for 1 min, 40°C for 1 min, 65°C for 8 min) and a final
extension cycle (65°C for 8 min). The DNA band patterns were evaluated by
electrophoresis with 1.5% agarose gels. Two strains were considered clonally
related when they had both the same numbers and the same locations of DNA
bands.
(iv) Beta-lactamase characterization. Isoelectric focusing (IEF) and PCR were
used for preliminary characterization of the beta-lactamases and beta-lactamase
genes present in E. coli isolates, respectively. IEF (PhastGel IEF 3-9; Pharmacia,
Barcelona, Spain) was performed to identify the numbers and isoelectric points
(pIs) of the beta-lactamases present (5, 18). Bacterial strains expressing known
beta-lactamases were included as controls. The IEF ranges were correlated to
those of TEM, SHV, or CTX-M beta-lactamases (G. Jacoby and K. Bush, Amino
acid sequences for TEM, SHV, and OXA extended-spectrum and inhibitor
resistant beta-lactamases [http://www.lahey.org/studies/webt.htm]).
PCR was used to determine whether blaTEM, blaSHV, and blaCTX-M were
present in each organism, as described previously (7, 22). Oligonucleotide prim-
ers were designed to amplify the genes encoding the most common subgroups
within the family of ESBLs and are shown in Table 1. All reactions were
performed in a 25-l volume with 2.0 U of FastStart polymerase (Roche Diag-
nostics, Mannheim, Germany). Cycling parameters included 4 min of denatur-
ation at 95°C, followed by 35 cycles of denaturation (95°C for 30 s), annealing
(58°C for 30 s for TEM and SHV, 62°C for 30 s for CTX-M-9, 60°C for 30 s for
CTX-M-10), and extension (72°C for 1 min), ending with a final extension period
of 72°C for 7 min. Control organisms included E. coli strains containing the
blaTEM-1, blaTEM-3, blaSHV-1, blaSHV-5, blaCTX-M-9, or blaCTX-M-10 gene. E. coli
J53 Rifr (negative control) was used as a negative control.
Statistical analysis. Continuous variables were compared by the Mann-Whit-
ney U test. Qualitative variables were compared by the chi-square test or Fisher’s
exact test, as appropriate; odds ratios and 95% confidence intervals were calcu-
lated. Logistic regression analysis was performed to determine the variables and
interactions that were significantly associated with the risk of infection with
ESBLEC. Variables were selected in a stepwise backward process, in which the
least significant variable was excluded at each step. The data were analyzed by
using the SPSS software package.
RESULTS
During the study period, ESBLEC strains were isolated
from 124 patients. Seventy-five patients had been admitted for
48 h or more when the sample had been obtained and were
excluded. Thus, 49 case patients were included in the study.
There was no apparent clustering of the case patients in terms
of their geographical distribution. The distribution of the case
patients throughout the study period is shown in Fig. 1. No
patient had to be excluded because of a lack of data.
ESBLEC strains were isolated from cultures of urine from
45 patients and cultures of blood from 6 patients (for 2 pa-
tients, ESBLEC strains were isolated from cultures of both
urine and blood). During the study period, ESBLEC strains
were 1.4 and 15.1% of all E. coli strains isolated from cultures
of urine and blood from outpatients, respectively.
TABLE 1. Nucleotide sequences of the oligonucleotides used for PCR amplification
Primer Nucleotide sequence (5 to 3) Position Product size (bp) Reference
blaTEM 1. 5-ATG AGT ATT CAA CAT TTC CG-3 208 1,075 30
2. 5-CTG ACA GTT ACC ATT GCT TA-3 1075
blaSHV 1. 5-GGG TTA TTC TTA TTT GTC GC-3 58 930 24
2. 5-TTA GCG TTG CCA GTG CTC-3 988
blaCTX-M9 1. 5-GTG ACA AAG AGA GTG CAA CGG-3 4 856 30
2. 5-ATG ATT CTC GCC GCT GAA GCC-3 860
blaCTX-M10 1. 5-CCG CGC TAC ACT TTG TGG-3 86 962 7, 29
2. 5-TTA CAA ACC GTT GGT GAC G-3 858
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The median age of the case patients was 70 years (age range,
15 to 92 years). Fifty-seven percent of the case patients were
female. Ten (21%) case patients were in the emergency de-
partment of the hospital when the sample was obtained, 7
(14%) were being attended to in the outpatient clinic, and 32
(65%) were in a primary care service. Twenty-seven patients
(55%) had been admitted to a hospital during the preceding
year. Only five patients (10%) were nursing home residents (all
of them had also been hospitalized during the previous year).
Other features of the case patients are shown in Table 2.
Thirty-seven patients (76%) were considered to have UTIs,
11 (22%) had asymptomatic bacteriuria, and 1 (2%) had acute
cholangitis. Twenty-eight patients received empirical treat-
ment, and this was considered appropriate, according to the in
vitro susceptibility testing data, for only 10 patients (amoxicil-
lin-clavulanic acid in 8 patients and ciprofloxacin in 2 patients).
The inappropriately indicated empirical antimicrobial agents
were ciprofloxacin (10 patients), levofloxacin (1 patient), cefu-
roxime (4 patients), cefotaxime (2 patients), and amoxicillin-
clavulanic acid (1 patient). The UTIs relapsed after antimicro-
bial treatment in five patients (13% of patients with UTIs).
Six patients (12%; five patients with UTIs and one patient
with cholangitis) had secondary bacteremia and needed to be
hospitalized. All six bacteremic patients received empirical in-
travenous treatment (three with amoxicillin-clavulanic acid,
two with cefotaxime, and one with levofloxacin), but the treat-
ment was appropriate in only two of them, according to the
results of in vitro susceptibility testing (amoxicillin-clavulanic
acid in both patients). The fever rapidly subsided in these two
patients. In the other four patients, the fever persisted until the
treatment was changed (to imipenem in three patients and to
piperacillin-tazobactam in one patient). All six patients were
finally cured.
Microbiological studies. The clonal relatedness of 55 iso-
lates (four patients were infected with 2 isolates and one pa-
tient was infected with 3 isolates) was studied by REP-PCR.
The range of the number of bands was 10 to 20. All strains
isolated from the same patient were indistinguishable. Forty-
nine different profiles were obtained by REP-PCR. Data on
the susceptibilities of the 49 clonally unrelated isolates to the
antimicrobial agents tested are shown in Table 3. Thirty-one of
the 49 isolates (64%) produced the CTX-M-9 ESBL. For three
of these strains it was not possible to amplify a CTX-M-related
gene, although both the pIs and phenotypic resistance (high-
level resistance to cefotaxime and low-level resistance to cefta-
zidime) suggested the presence of a CTX-type ESBL. No
CTX-M-10 ESBL was detected. TEM and SHV ESBLs were
FIG. 1. Distribution of case patients during the study period (January 2001 to June 2002). Jan, January; Feb, February; Mar, March, Apr, April;
Jun, June; Jul, July; Aug, August; Sep, September; Oct, October; Nov, November; Dec, December.
TABLE 2. Features of 49 patients infected with
community-acquired ESBLEC
Feature No. (%) ofpatients
Female sex ................................................................................... 28 (57)
McCabe classification of underlying disease
Nonfatal underlying disease................................................... 35 (71)
Ultimately fatal underlying disease....................................... 14 (29)
Rapidly fatal underlying disease ........................................... 0
Diabetes mellitus......................................................................... 20 (41)
Chronic respiratory disease ....................................................... 5 (10)
Chronic liver disease................................................................... 1 (2)
Neoplasia...................................................................................... 6 (12)
Recurrent UTIs ........................................................................... 28 (57)
Permanent urinary catheter ....................................................... 11 (22)
Surgery (in preceding year) ....................................................... 4 (8)
Immunosuppressive drugs.......................................................... 0
Exposure to antimicrobial agents
Previous antimicrobial treatment (in last 2 mo)................. 33 (67)
More than two cycles of antimicrobial treatment
(in preceding year).............................................................. 31 (63)
Aminopenicillins...................................................................... 4 (8)
Oral cephalosporins ................................................................ 5 (10)
Fluoroquinolones .................................................................... 20 (41)
Aminoglycosides...................................................................... 2 (4)
Trimethoprim-sulfamethoxazole ........................................... 4 (8)
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both detected in nine clones each (18%). No epidemiological
relation was found among case patients infected with isolates
sharing the same type of ESBL. Among the 27 patients with
previous hospitalizations, CTX, TEM, and SHV ESBLs were
found in 18 (67%), 6 (22%), and 3 (11%) patients, respectively.
Among the five nursing home patients, four were infected with
a CTX-producing clone and one was infected with an SHV-
producing clone.
Case-control study. The results of univariate comparisons of
the case patients and the controls are shown in Table 4. The
multivariate analysis selected diabetes mellitus, the use of fluo-
roquinolones in the previous 2 months, recurrent UTIs, admis-
sion to a hospital during the preceding year, and older age in
males as independent factors associated with an increased risk
of isolation of ESBLEC. Eighty-two percent of the case pa-
tients had two or more of these risk factors. When only case
patients infected with a CTX-producing clone were consid-
ered, the risk factors identified by multivariate analysis were
older age, a higher Charlson index, and previous fluoroquino-
lone use. The results obtained with both multivariate models
are shown in Table 5.
DISCUSSION
Infections due to ESBL-producing K. pneumoniae and
ESBLEC in nursing home residents are well-known problems
(32). However, even though some recent data suggest that
infections due to ESBLEC in nonhospitalized patients might
be emerging (1, 8, 9, 11, 14, 15), the epidemiology of these
infections outside nursing homes had not been studied. Our
study confirms the emergence of ESBLEC as a cause of infec-
tion in outpatients outside nursing homes.
E. coli is the most frequent cause of community-acquired
UTIs and is frequently found to be responsible for intra-ab-
dominal and soft tissue infections. Thus, resistance to com-
monly used antimicrobials in E. coli represents a problem for
TABLE 3. Susceptibility data for 49 ESBLEC strains to different antimicrobial agents
Antimicrobial agent
MIC (mg/liter)a % of strains
susceptible50% 90% Range
Amoxicillin-clavulanic acid 16/8 32/16 2/1–256/128 48
Ciprofloxacin 8 64 0.06–64 22
Gentamicin 0.5 64 0.06–128 74
Amikacin 1 8 0.125–128 96
Imipenem 0.03 0.06 0.015–0.125 100
Cefotaxime 128 512 2–512
Ceftazidime 16 128 0.125–256
Cefoxitin 4 32 1–128 84
Trimethoprim-sulfamethozaxole 32/608 32/608 1/19–32/608 29
a 50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.
TABLE 4. Crude analysis of potential risk factors for community-acquired ESBLEC infection
Variable Case patients (n  49) Controls (n  98) OR (95% CI)a P value
Age (yr [mean, SD]) 65, 24 35, 24 0.001
Male sex (% of patients) 43 19 3.1 (1.4–6.6) 0.003
Charlson index (mean) 1.82 1.52 0.001
% of patients with:
Diabetes mellitus 41 6 10.5 (3.8–28.8) 0.001
Chronic pulmonary disease 18 5 4.1 (1.3–13.2) 0.01
Liver disease 2 2 1.0 (0.0–11.3) 1.0
Neoplasia 12 1 13.5 (1.5–115.8) 0.009
Recurrent urinary tract infections 57 19 5.5 (2.6–11.8) 0.001
Permanent urinary catheter 22 0 0.001
Previous antimicrobial treatment 67 9 20.3 (8.2–50.6) 0.001
More than two cycles of antimicrobial treatment 63 8 19.3 (7.6–48.9) 0.001
% of patients treated with:
Aminopenicillins 8 2 4.2 (0.7–24.1) 0.07
Oral cephalosporins 10 1 11.2 (1.2–97.1) 0.01
Fluoroquinolones 41 5 12.8 (4.4–37.2) 0.001
Trimethoprim-sulfamethoxazole 8 1 8.6 (0.9–79.3) 0.04
% of patients with:
Hospital admission during last year 55 1 15.9 (6.1–41.3) 0.001
Nursing home residency 10 0 0.004
a OR, odds ratio; CI, confidence interval.
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the treatment of these infections. As expected, ESBLEC
mainly caused UTIs in our study. Few oral antimicrobials that
are active against these organisms are available: all of the
organisms were resistant to ampicillin and cephalosporins, and
many of them were resistant to ciprofloxacin and/or tri-
methoprim-sulfamethoxazole. Amoxicillin-clavulanic acid was
the most active oral agent among those tested in our study, but
it was active against only half the isolates.
The fact that ESBLEC was the cause of bacteremia in some
of our patients is even more worrying. Some antimicrobial
agents commonly recommended for the treatment of commu-
nity-acquired urinary tract or intra-abdominal sepsis (extend-
ed-spectrum cephalosporins, fluoroquinolones) are probably
not useful against ESBLEC (24, 26). Four of the six bacteremic
patients in our series received inadequate empirical treatment,
and sepsis was not controlled until the treatment was changed.
Treatment with a combination of a beta-lactamase–beta-lacta-
mase inhibitor was successful in three of the patients, but these
combinations are not usually recommended, as a high mortal-
ity rate has been found in some nonrandomized studies (23,
28). Thus, a carbapenem is usually recommended as the drug
of choice for the treatment of severe infections due to ESBL-
producing organisms (26). However, the emergence of carba-
penem-resistant organisms may be a concern.
In our study, several risk factors for infections due to
ESBLEC in nonhospitalized patients were identified: previous
admission to a hospital, diabetes mellitus, recurrent UTI, flu-
oroquinolone use during the previous 2 months, and older age
in male patients. Fifty-five percent of the patients had been
admitted to a hospital during the previous year. The horizontal
transmission of ESBLEC during the previous hospital stay is
improbable, since we found no clonal relationship among the
strains obtained from those patients and those obtained from
patients with nosocomially acquired ESBLEC (data not
shown). A previous hospital admission might also be an indi-
rect marker of other predisposing factors (underlying diseases,
antimicrobial use). Nevertheless, almost half of the case pa-
tients had not been hospitalized during the past year, nor had
they been in nursing homes, so their infections can be consid-
ered truly community acquired. Clonal dissemination of uro-
pathogenic trimethoprim-sulfamethoxazole-resistant E. coli in
the community has been described previously (16), but we
found no clonal relatedness among the ESBLEC isolates in our
study. However, as ESBLs are usually encoded on plasmids, we
cannot discard the possibility of plasmid transmission between
strains (32). Further studies are being conducted to elucidate
this possibility.
Many ESBL types are geographically distributed (4). It is
remarkable that 64% of the community-acquired strains pro-
duced a CTX-M-9-like ESBL. This ESBL, along with CTX-
M-10 and CTX-M-14, have previously been described in Spain
(2, 7) but have never been as prevalent in these types of strains.
The sequencing of the genes that encode the ESBLs is in
progress. It is also important to point out that a significant
percentage of the ESBLEC isolates in our study produced
TEM or SHV. Most of these enzymes have been related either
to nosocomial infections or to nursing home-related infections
(3).
In our study previous fluoroquinolone use was a risk factor
both for the acquisition of ESBLEC and for the specific ac-
quisition of a CTX-producing ESBLEC. Previous ciprofloxacin
and/or trimethoprim-sulfamethoxazole treatment was also a
risk factor for colonization with ESBL-producing organisms in
nursing home patients (32). These antimicrobials may select
for ESBLEC in previously colonized patients, since ESBL pro-
duction and resistance to these antimicrobials are linked. The
plasmids encoding ESBLs also frequently encode the genetic
determinants of trimethoprim-sulfamethoxazole resistance;
the association between ESBL production and quinolone re-
sistance is more complex (17, 25). The prevalence of ESBLEC
colonization in the community is not known.
Our study has some limitations. Our case patients probably
represent only the most visible part of the population harbor-
ing these organisms. Systematic prospective surveillance for
the detection of colonized patients is desirable for studying
nosocomially acquired antimicrobial agent-resistant organisms
(27), but is not possible in the community setting. However, we
believe that our results might provide useful information for
clinical purposes. We did not choose as controls patients in-
fected with non-ESBL-producing E. coli, as such a design over-
estimates the implications of previous antimicrobial use (12,
27). Recall bias is always possible in these kinds of studies. We
TABLE 5. Multivariate analysis of factors associated with increased risk of community-acquired infection due to ESBLEC
Patient group and variablea  coefficient OR (95% CI)b P value
All case patients
Diabetes mellitus 1.7 5.5 (1.6–18.7) 0.006
Fluoroquinolone use 2.0 7.6 (1.9–30.1) 0.003
Recurrent urinary tract infections 1.5 4.5 (1.3–15.1) 0.01
Admission during last year 2.9 18.2 (5.3–61.6) 0.0001
Age (yr) and sex 0.03 1.03 (1.01–1.05) 0.001
Age (yr) 0.003 1.0 (0.9–1.03) 0.7
Gender 0.2 1.2 (0.5–29.3) 0.8
Case patients infected with CTX-M-9-producing clone
Fluoroquinolone use 1.6 5.2 (1.4–19.3) 0.01
Age (yr) 0.03 1.03 (1.01–1.06) 0.004
Charlson index 0.5 1.6 (1.1–2.5) 0.01
a Age and Charlson index are continuous variables. All other variables except sex are dichotomous and are codified as 0 (absence), or 1 (presence of the feature);
sex is codified as 0 (female) or 1 (male).
b OR, odds ratio; CI, confidence interval.
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tried to avoid recall bias in several ways: by not informing the
patients or primary care doctors of the purpose of the study
until the end of the interview and by using a detailed question-
naire on previous antimicrobial use.
The results of our study may have two main practical con-
sequences. First, interventions directed at decreasing the use
of fluoroquinolones for the treatment of UTIs in patients with
other risk factors (diabetes mellitus, recurrent UTIs, admission
to a hospital during the preceding year) should be attempted in
our area. Second, studies designed to predict the risk of sepsis
due to ESBLEC in the individual patient should be developed
to identify those patients who should receive empirical treat-
ment with an agent with activity against these organisms. In the
meantime, in areas where infections due to ESBLEC are oc-
curring, it might be prudent to consider therapy with activity
against these organisms in the empirical treatment of high-risk
patients with severe community-acquired urinary tract sepsis.
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